Role of Cholinergic Signaling in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 139 of the 141 references it cites were found in a registry or an index.
Abstract
Acetylcholine, a neurotransmitter secreted by cholinergic neurons, is involved in signal transduction related to memory and learning ability. Alzheimer’s disease (AD), a progressive and commonly diagnosed neurodegenerative disease, is characterized by memory and cognitive decline and behavioral disorders. The pathogenesis of AD is complex and remains unclear, being affected by various factors. The cholinergic hypothesis is the earliest theory about the pathogenesis of AD. Cholinergic atrophy and cognitive decline are accelerated in age-related neurodegenerative diseases such as AD. In addition, abnormal central cholinergic changes can also induce abnormal phosphorylation of ttau protein, nerve cell inflammation, cell apoptosis, and other pathological phenomena, but the exact mechanism of action is still unclear. Due to the complex and unclear pathogenesis, effective methods to prevent and treat AD are unavailable, and research to explore novel therapeutic drugs is various and active in the world. This review summaries the role of cholinergic signaling and the correlation between the cholinergic signaling pathway with other risk factors in AD and provides the latest research about the efficient therapeutic drugs and treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second-generation AChEIs, including donepezil (4), rivastigmine (5), galantamine (6), are more selective. They exhibited fewer side effects or improved pharmacokinetic profiles, establishing them as first-line drugs for AD.98,400”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is a progressive neurodegenerative disorder and the leading cause of dementia among older adults, characterized by a gradual decline in cognitive function, memory loss, and behavioral changes, ultimately leading to complete dependence on caregivers [7].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these, neurons of the nucleus basalis of Meynert (NBM) are particularly vulnerable, and their degeneration leads to profound reductions in choline acetyltransferase (ChAT) activity within projection areas such as the cerebral cortex and hippocampus, regions essential for learning, memory, and attention [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This hypothesis suggests that a reduction in the synthesis and release of ACh impairs its physiological functions, which are critical for learning, memory, and other cognitive processes.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“The cholinergic hypothesis, one of the earliest and most influential theories of AD, proposed that the characteristic cognitive deficits of the disorder arise primarily from degeneration of cholinergic neurons in the basal forebrain [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hafez, H. S., Ghareeb, D. A., Saleh, S. R., Abady, M. M., Demellawy, M. E., Hussien, H. M., & Abdel-Monem, N. M. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4690-x · Cited by 85
RetractedSemwal, B. C., & Garabadu, D. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08615-1 · Cited by 9 · cited 2×
“Aβ can induce mitochondrial toxicity in the brain, resulting in cognitive dysfunction [5].”
BackgroundRetractedNEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311 · cited 1×
“According to clinical data in recent years, the brains of patients with AD show severe neurodegeneration and reduction of cholinergic neurons and a severe deficiency of Ach; acetylcholine transferase activity is significantly decreased, which further illustrates the damage to the cholinergic system in patients with AD…”
BackgroundEfficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Román, G. C., Jackson, R. E., Gadhia, R., Román, A. N., & Reis, J. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.08.005 · Cited by 421
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312 · cited 1×
“AD is a major cause of dementia which is a common disease among the elderly, starting with an irreversible decline in episodic memory and then a more general decline in overall cognitive ability [2,3].”
BackgroundLiu, Y., Zhang, Y., Zheng, X., Fang, T., Yang, X., Luo, X., Guo, A., Newell, K. A., Huang, X.-F., & Yu, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1141-5 · Cited by 285 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
BackgroundLuo, H., Xiang, Y., Qu, X., Liu, H., Liu, C., Li, G., Han, L., & Qin, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00395 · Cited by 264 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
Background
Research works printed but not linked: 1
- Yu, 2019, Protective roles of isoastilbin against Alzheimer’s disease via Nrf2mediated antioxidation and antiapoptosis, Int. J. Mol. Med., 43, 1406
Cited by
Items 901–1,000 of 1,000
Fan, X., Wu, J., & Mao, J. (2026) · International Journal of Pharmacology · doi:10.31083/ijp46379
Genome-Wide Association Study Identifies Genetic Loci Involved with Sleep Fragmentation
Maxwell, A. M. (2025) · TSpace (University of Toronto)
2,3,4-Trihydroxybenzophenone Disassembles Amyloid β Aggregates and Ameliorates Synaptic Deficits
Cho, E., Youn, K., Kwon, H., Bae, H. J., Moon, M., Jun, M., & Kim, D. H. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18030320
树鼩乙酰胆碱转移酶免疫阳性神经元表达全脑图谱以及与小鼠的比较
Yi-Lin, P., Wang, S.-D., Shuai-Deng, W., Wang, Y., Shan-Shan, Z., Shan-Shan, Z., Shuang-Shuang, L., Zi-Ran, H., Qi-qi, X., Yue-Xiong, Y., et al. (2026) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2025.501
lncRNAs: key player in Aβ deposition
Wang, R.-M., & Wang, Z. (2026) · RNA Biology · doi:10.1080/15476286.2026.2639017
“However, the underlying molecular mechanism that explains the imbalance between Aβ production and clearance is still unclear. β and γ secretases cleave APP to produce Aβ [6,7], which is cleared by glial cell-mediated autophagy [8,9].”
Kumar, R., ., S., Malik, J., Kumar, K., Kumar, S., Kumar, M., ., H., Bansal, A., & Verma, M. (2026) · Chemical Biology Letters · doi:10.62110/sciencein.cbl.2026.v13.1754
Robinson, H., Yassin, M., Robinson, D., Qawasmi, F., Mahamid, A., & Khatib, M. (2026) · Preprints.org · doi:10.20944/preprints202603.1055.v1
Biswas, K., Moore, C. M., Rogers, H., Wani, K. A., Mushtaq, A., Pukkila-Worley, R., Higgins, D. P., Walker, A. K., Mullen, G. P., Rand, J. B., et al. (2026) · eLife · doi:10.7554/elife.107726.2
Misciagna, S. (2025) · Directory of Open access Books (OAPEN Foundation)
Grzelczyk, J., Pérez‐Sánchez, H., Carmena‐Bargueño, M., Gałązka‐Czarnecka, I., Budryn, G., Hernik, D., Brenna, E., & Boratyński, F. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109770
Targeting oxidative stress and neurodegeneration: the role of Putranjiva roxburghii in Alzheimer’s
Bhardwaj, V., Goel, F., & Rajput, M. S. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02200-x
Mahadik, N. (2025) · Open Access Institutional Repository at Robert Gordon University (Robert Gordon University) · doi:10.48526/rgu-wt-3316026
Drug Discovery for Alzheimer’s Disease: Current Status
Wolfe, M. S. (2026) · Topics in medicinal chemistry · doi:10.1007/7355_2026_186
Mani, R., Amo-Tweneboah, C., Kaiteris, A., Lebens, R. S., Chough, I., & Skopicki, H. A. (2026) · Aging advances. · doi:10.4103/agingadv.agingadv-d-25-00037
Schmidt-Morgenroth, I. (2023) · theses.fr (ABES) · doi:10.70675/f89a7c1ez54acz49f7zbb58z4be7d3ab8c1f
Biswal, B., Satapathy, B. S., Pattnaik, S., & Maharana, L. (2026) · PharmaNutrition · doi:10.1016/j.phanu.2026.100493
Understanding the Link Between Environmental Pollutants, Brain & Behavior
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-7781-3
Derbak, L., Mohammed, A. S., Rabhi, M. L., Bendif, H., Ayad, R., Rebbas, K., Demirtaş, İ., Chaudhary, A. A., Elfalleh, W., & Garzoli, S. (2026) · Food Analytical Methods · doi:10.1007/s12161-026-03089-6
Shao, D., Liang, S., Xiong, Y., & Liang, G. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag153
“Acetylcholinesterase (AChE), the enzyme responsible for degrading ACh in the synaptic cleft, exhibits elevated activity in AD, thereby accelerating ACh breakdown and further exacerbating cholinergic deficiency (Chen et al .”
Laskar, R. U. (., Meena, B. S., Roy, A., & Borah, A. (2026) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2026.2647201
“Clinical evidence indicates that acute levels of ACh shortage, diminished cholinergic activity and severe neurodegeneration in the brains of AD patients [14].”
Mewada, D., Tomar, M., & Goyal, M. (2026) · Premier journal of science. · doi:10.70389/pjs.100272
Ojelabi, A. O., Onodugo, C. A., Babalola, A. O., Otenaike, O. E., Brai, B. I. C., Ajiboye, B. O., Ajuwon, O. R., & Bamisaye, F. A. (2026) · Journal of Science Technology and Innovation Research · doi:10.51459/jostir.2025.1.special-issue.0241
Kumar, I., Rani, D., & Pathania, K. (2026) · Current Trends in Pharmacy and Pharmaceutical Chemistry · doi:10.18231/j.ctppc.39626.1776405949
Arora, H. S., Dhakal, S., Psarellis, Y. M., Chandrasekaran, S., Mavroudis, P. D., & Pillai, N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.14.718573
“…with research exploring the augmentation of synaptic acetylcholine supply to address the cholinergic deficits characteristic of AD pathology [77]–[79] Several identified hits correlate with pharmacological strategies aimed at addressing the neuronal hyperexcitability [80]–[82] and calcium…”
Ahn, J. W., Yoon, E., Kim, H. S., Choi, Y., Jeong, J., Damodar, K., Yoo, Y., Park, D., & Joo, S. S. (2026) · Scientific Reports · doi:10.1038/s41598-026-49541-9
“In addition, HSN-G1 improves cholinergic function, as evidenced by increased expression of ChAT and elevated acetylcholine levels 42,43 .”
García-Sanchoyerto, M. (2026) · DeustoTeka
Usman, A. S., Nassir, C. M. N. C. M., Hamid, H. A., Manoharan, S. D., Hein, Z. M., Hasan, M. K. N., Norazit, A., Moklas, M. A. M., & Mehat, M. Z. (2026) · Translational Research in Anatomy · doi:10.1016/j.tria.2026.100485
Ugwah-Oguejiofor, C. J., Okechukwu, P. N., Mathias, S. N., Ofokansi, M. N., & Janakiraman, A. K. (2026) · Studies in natural products chemistry · doi:10.1016/b978-0-443-49144-3.00007-1
Re-Purposing a Rho-Associated Coiled-Coil Kinase (ROCK) Inhibitor for Alzheimer’s Disease
Cambi, X., Liu, Z., Guo, K., & Xia, W. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093379
“However, the effects of these drugs diminish over time and do not address the underlying pathology [10].”
de Oliveira, T. M., Bento, L. D. P., Wiermann, I. S. D. M., Fonseca, B. D. S., Tsui, G. S., de Jesus, C. J. P., Sales, R. O., Prado, M. A. P., de Castro, M. S., Moura, J. P. R., et al. (2026) · ACS Omega · doi:10.1021/acsomega.6c00778
Cho, E., Lee, S., Lee, H., Kim, J., Kwon, Y. W., Hoe, H., Kim, D., & Yoon, J. H. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101580
Barros, T. G. R., Grossi, L. B., Campos, M. L. D. S., Cardoso, I. B.-H. N., Teixeira, A. L., de Miranda, A. S., & Toscano, E. C. D. B. (2026) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.70077
Santos, A. C. C., Corrêa, J. L., Duarte, R., Malta, S. M., Rodrigues, T. S., Santos, D. D. O., de Faria, P. R., Mascarenhas, F. N. A. D. P., Zanon, R. G., Cassemiro, N. S., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-52291-3
“Cholinergic dysfunction represents another central feature of AD pathophysiology 50,51 .”
The Microbiome and Neurotransmitter Regulation: A Double-Edged Sword
Paul, D., & Agrawal, R. (2026) · Springer eBooks · doi:10.1007/978-981-95-7494-0_7
Diabetes - Associated Cognitive Decline: Mechanistic Insights and Emerging Role of Medicinal Plants
Nimbalkar, A., Ubale, V., Kature, D., & Patil, R. (2026) · International Journal of Pharmacology and Clinical Research · doi:10.33545/26647613.2026.v8.i5a.253
Bahloul, A., Messaâd, M., Smaoui, S., Khemakhem, B., & Abdelhedi, M. (2026) · Journal of Materials Chemistry B · doi:10.1039/d5tb02912k
M‐Atoom, A., Ahmed, M. H., Al-Hasnaawei, S., Malathi, H., Maharana, L., Nanda, A., Arora, V., & Singh‐Chauhan, A. (2026) · Polymer International · doi:10.1002/pi.70141
Vaja, R., Ramachandran, A. V., & Baxi, D. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.112139
Ansari, S., Khali, A., Joshi, B. C., & Uniyal, S. (2026) · Physiological Mini Reviews · doi:10.2174/0116695410415209251114033740
Neurosteroid-Mediated Neuroprotection via mTORC1/AMPK/BDNF Signaling Pathway in Alzheimer’s Disease
Khobrani, M. A., Al‐kuraishy, H. M., Hussein, N. R., Mustafa, A. M., & Batiha, G. E. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05918-5
Sharma, S., Kumar, V. V. R., Arulsamy, S., Kumar, S., & Wadhwa, P. K. (2026) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2026.111765
Sharma, D. K., & Prasad, C. S. (2026) · Journal of drug targeting · doi:10.1080/1061186x.2026.2683967
Multitarget Actions of Pentacyclic Triterpenic Acids in Alzheimer’s Disease: Mechanistic Insights
Sharma, N., & An, S. S. A. (2026) · Molecules · doi:10.3390/molecules31122018
A review on thymoquinone: a promising therapeutic molecule in Alzheimer's
Kaur, S. D., SINGH, V. A., Kaurav, H., Nangare, S., & Vihal, S. (2026) · Nutritional Neuroscience · doi:10.1080/1028415x.2026.2682949
Kencü, S. N., Budak, Ü., & Baş, H. (2026) · Plant Biosystems - An International Journal Dealing with all Aspects of Plant Biology · doi:10.1007/s44473-026-00197-3
“When treating neurodegenerative illnesses like AD, this pathway is thought to be crucial (Chen et al. 2022a).”
Sdougkou, K., Rekka, E. A., & Papagiannopoulou, D. (2026) · ChemMedChem · doi:10.1002/cmdc.70343
Preclinical and Clinical Studies
Kalayil, N., Nadar, S., Thakor, E., & Nadar, J. (2026) · Wiley eBooks · doi:10.1002/9781394360260.ch14
Phosphonates as Modulators of Brain Chemistry
Braga, S. S., Santos, N. E., Almeida-Santos, M., Figueira, F., & Paz, F. A. A. (2026) · Medicinal Research Reviews · doi:10.1002/med.70070
“Cholinesterases are a classic therapeutic target for AD with research remaining active until the present day [42] even though the cholinergic hypothesis of disease development dates back from the 1980s [37, 43].”
Aouidene, M., Bouabidi, N., Jebri, D., Znati, M., Jalouli, M., Othman, M., & Jannet, H. B. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146848
Nath, R., Chakraborty, A., Akhtar, M. J., Maity, I., Ganguly, S., Nehra, B., Ashique, S., Khan, S. A., Tariq, M., Bakshi, S., et al. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11618-y
Huang, S.-H., Akter, M., Milton, C. B., & Shen, M. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c04969
Gogoi, H., & Dey, P. (2026) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2026.100795
PCSK9 in bridging metabolism and neurodegeneration: a new paradigm for alzheimer’s treatment
Sood, S., Singh, S., & Singh, T. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01900-1
“Thus, when it comes to AD, the cholinergic system has been one of the primary areas of interest (Majdi et al. 2020; Chen et al. 2022).”
Muralidhara, M., Vismaya, & Kumar, V. L. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106204
Girish, M., Adhoni, S. A., Meghana.M, L, K. K. L. K. K., Arya Viswanath, M., Yadav, A. K., R, N. K., Poornima, D., B, V. R., M, A. K. K., et al. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.55s.131
Kazeminasab, F., Zafarmand, O., & Bagheri, Z. (2026) · Journal of Translational Medical Research · doi:10.66224/jbums.32.4.266
IL-4 in Alzheimer’s Disease—Mechanisms and Therapeutic Potential
Liu, G., Li, W., Chen, J., Xu, S., Liu, X., Wang, Z., Yang, Q., Xie, A., & 杜艳军 (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06003-7
Shahbaz, M. A. H., Khalil, S., Al‐Saeedi, S. I., Kumar, A. C. S., Afzal, A. M., Mumtaz, S., & El‐Sabban, H. A. (2026) · Diamond and Related Materials · doi:10.1016/j.diamond.2026.113870
Freire‐Flores, D., Ramos‐Henderson, M., Burgos, H., & Carvallo, C. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261462138
“32,33 While high anticholinergic burden has been linked to increased dementia risk in large cohort studies, 32,33 systematic reviews highlight methodological heterogeneity and limitations in causal inference, including confounding by indication and reverse causation 34 Furthermore, studies in…”
Islam, S. S. L. K. M. M. (2026) · International Journal of Biosciences (IJB) · doi:10.12692/ijb/28.6.60-67
Gohar, N., Abbas, M., Masaud, S. M., Zulfiqar, I., Jabeen, H., Malik, N. S., & Nadeem, H. (2026) · ACS Omega · doi:10.1021/acsomega.6c01108
“17 One of the earliest and most widely accepted explanations of AD pathology is the cholinergic hypothesis, 18 which attributes memory and learning deficits to reduced levels of acetylcholine (ACh) 15 in the hippocampus and cortex.”
Anukanon, S., Teerapattarakan, N., & Hankittichai, P. (2026) · Science Essence Journal · doi:10.69523/sej.2026.42.17130
“By modulating mTOR activity, NGF not only supports neuronal survival but also mitigates key pathological processes associated with both the amyloid and tau hypotheses [12].”
Cavalcante, T. R., Maciel, J. B., Alves, A. M. B., Silva, J. A. D., Silva, J., Silva, T. S., dos Santos, R. C. R., Guedes, J. M., Silva, J. B., Júnior, J. R. C., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9849150/v1
Espinosa, G. M. C. (2026) · Ibero Ciencias - Revista Científica y Académica · doi:10.63371/ic.v5.n2.a1332
Lu, Z., Gao, Y., Wei, M., Ding, S., Liu, R., Deng, X., Lin, S., & Kong, L. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.109421
Stylopine as multi-target anti-Alzheimer agent
Nour, H., Mounadi, N., Samadi, A., & Chtita, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-61364-2
Alzheimer’s Disease: Molecular Pathophysiology and Current Therapeutic Management
Shingade, S. S., Mandhare, T. A., Mujumale, J. S., Kashid, P., & Otari, K. V. (2026) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3523
Tau Protein in Alzheimer's Disease
Mukherjee, M., Dhara, S., Jana, A., & Roy, T. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010005
Pal, T., Mukherjee, S., Karati, D., Pahari, N., Hossain, C. M., & Naskar, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010017
Exploring thiazole conjugates as cholinesterase inhibitors for Alzheimer’s disease treatment
Dabas, A., Yadav, P., & Singh, R. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2699679
Singh, C. (2026) · Journal of chemical health risks · doi:10.52783/jchr.v16.i3.14783
Liu, Y., Fu, T., Li, W., Peng, K., Li, M., Li, W., Feng, Y., & Wu, X. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100455
Qin, Y., Dong, X., Zhang, C., & Nao, J. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158586
A Recent Update on Kojic Acid-Based Derivatives for the Treatment of Alzheimer’s Disease
Ritika, R., Singh, Y. P., & Sharma, R. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.64s.110
Farrokhi, M. R., Askari, A., SoukhakLari, R., & Moosavi, M. (2026) · BMC Neuroscience · doi:10.1186/s12868-026-01027-0
“Cholinergic signaling plays a well-established role in hippocampal-dependent memory processes, and its disruption has been strongly implicated in deficits of episodic and recognition memory [41].”
Awwad, Z. M. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02345-9
“Traditional therapeutic agents that act by boosting cholinergic pathways in AD are used in the treat - ment of AD, however it was previously reported that cholin - ergic agents have limited efficacy in AD (Chen et al. 2022).”
Li, Y., Alhoqail, W. A., Mickymaray, S., & Li, F. (2026) · Dose-Response · doi:10.1177/15593258261471150
“37,39 In that regard, the sesquiterpene lactone cnicin becomes a potential neurotherapeutic candidate.”
Hematological Considerations in Immunotherapy for Alzheimer's Disease
Kumar, R. R., Pandey, R., Antal, S., Rani, S., & Alam, M. S. (2026) · Wiley eBooks · doi:10.1002/9781394336241.ch8
El-Mezayen, N. S., Eesa, Y. A., Hassan, W. A., Aly, D. A., Saafan, Y. S., Khedr, E. M., Sherief, A., & Elkordy, E. A. (2026) · Scientific Reports · doi:10.1038/s41598-026-55386-z
“Cortical tissue was selected as AD is primarily characterized by impairment of cortical cholinergic innervation 73–75 .”
Selvaraj, N. R., Vijaya, B. S., Nandan, D., San, S., Nair, S. S., Nair, B. G., Venugopal, P., Aradhya, R., & Nair, V. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156642
“The inhibition of AChE prevents the hydrolysis of acetylcholine, thereby enhancing cholinergic neurotransmission [75–78].”
Frota, L. S., Barbosa, S. I. C. G., Prado, J. C. S., Ishiki, H. M., Fontenelle, R. O. D. S., & de Morais, S. M. (2026) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765202620250618
Flavonoids and neurodegeneration: Structure-activity relationship and therapeutic insights
Paragas, D. S., Ortinero, C., Feliciano, M. A. M., Lazaro, S. E., Quitos, L. S., Gonzales, R. L., Hsieh, C.-Y., Chen, B.-Y., Hsueh, C., & Tsai, P. (2026) · Studies in natural products chemistry · doi:10.1016/b978-0-443-49142-9.00010-x
Early Amyloid-β Toxicity Disrupts Nervous System Connectivity During Aging in Caenorhabditis elegansPreprint
Yadav, D. K., Connor, C. W., & Gabel, C. V. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.27.740981
Junaid, M., Ashraf, S., Arshad, A., Bakhtiari, M. N., Hussain, S., & Shahnaz, G. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108758
Jackson, B. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1895931
“…when only thinking about attention and encoding, Alzheimer’s research has historically indicated a prominent role for noradrenergic and cholinergic signaling in disease and symptom-modifying pharmaceutical interventions (Bastin et al., 2019; Chen et al., 2022; David et al., 2022; Malhotra, 2019).”
Sharma, S., Sharma, S., Raghuvanshi, V., Kumari, S., Singh, S., Butcher, R. J., Srikrishna, S., & Katiyar, D. (2026) · RSC Advances · doi:10.1039/d6ra01662f
Rathi, A., & Singh, L. (2026) · International Journal of Aquatic Research and Environmental Studies · doi:10.70102/ijares/v6s5/6-s5-1745
Sharma, R., Banerjee, S., Arya, R., Tiwari, V. K., Prajapati, P. K., Chen, K., & Sharma, R. (2026) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2026.08.001
Scaria, A., Elphine Prabahar, A., & Siju, E. N. (2026) · Genetics and Molecular Research · doi:10.4238/0pmk0226
Exploring Plant-derived Compounds as Potential Sources of Natural Acetylcholinesterase Inhibitors
Usmani, Q. A., Siddiqui, N., Saifi, A., Sharma, A., Anurag, & Parihar, V. K. (2026) · World Journal of Traditional Chinese Medicine · doi:10.4103/wjtcm.wjtcm_73_25
Ambamba, B. D. A., Jonathan, M. M. N., Marc, A. F. Y., Sandrine, N. M., Reine, N. M. I., Emmanuel, N., Laurent, N. A., Blonde, N. E. M. L., Alexandra, E. E. F., Ella, F. A., et al. (2026) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2026.08.007
Yuan, R., Liao, G., Su, S., Shan, J., & Tang, S. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261477008
“…disrupted acetylcholine transmission and synaptic dysfunction, 19 which is highly consistent with the cognitive impairment typical of AD patients, 20 thus reinforcing the signi fi cance of enhancing synaptic resilience as a therapeutic strategy beyond traditional acetylcholinesterase inhibition.”
Raj, S. N., Natnan, M. E., Lou, W. P., Mediani, A., Tencomnao, T., & Baharum, S. N. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12565-5
Çimentepe, Ö. Ö., Yasar, E., Necip, A., Çimentepe, M., Yiğin, A., Yıldırım, M., & Kılıç, A. (2026) · Polyhedron · doi:10.1016/j.poly.2026.118345
Emerging Advances in Neuropharmacology: Novel Therapeutic Targets for Neurodegenerative Disorders
Nisha, & Qadir, S. (2026) · Current Pharmaceutical Research · doi:10.63785/cpr.2026.2.2.271291
“Salient neuropathological exemplars in a continuum of neurodegenerative conditions, such as the Alzheimer disease, are degenerative alterations in the basal forebrain cholinergic neurons, combined with reduced acetylcholine transmission [88].”
Dönmez, M. O., Şener, A., Ersoy, Ş. K., Marzi, M., & Şener, G. (2026) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.6375
“In the brain, acetylcholine (ACh) is involved in several physiological functions including learning, memory, attention, and sensory information processing [3].”
Metadata
- Authors
- Chen, Z.-R., Huang, J.-B., Yang, S.-L., & Hong, F.-F.
- Affiliations
- Nanchang University (CN)
- Experimental Center of Pathogen Biology, Nanchang University, Nanchang 330031, China
- Corresponding author
- Yang, Shu-Long
- Hong, Fen-Fang
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-03-10
- Volume
- 27
- Issue
- 6
- Pages
- 1816
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8949236
- OpenAlex
- W4220945110
- Cited by
- 922
- References
- 141
- Citations by year
- 2026: 256 · 2025: 347 · 2024: 202 · 2023: 87 · 2022: 29
- FWCI
- 22.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (82060661, 81660751, 81660151)
- Jiangxi Provincial Natural Science Foundation of China (20212BAB206092)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic neurotransmission, acetylcholine, cholinergic hypothesis, cognitive decline, tau phosphorylation, neuroinflammation, apoptosis, Alzheimer's disease pathogenesis, Alzheimer's disease therapeutics
- MeSH terms
- Acetylcholine, Alzheimer Disease, Humans, Signal Transduction, Cholinergic Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.